

Datasheet: MCA477SBB675

### **BATCH NUMBER 100006936**

| Description:  | MOUSE ANTI HUMAN HLA DP DQ DR:StarBright Blue 675 |  |  |  |
|---------------|---|--|--|--|
| Specificity:  | HLA DP DQ DR                                      |  |  |  |
| Format:       | StarBright Blue 675                               |  |  |  |
| Product Type: | Monoclonal Antibody                               |  |  |  |
| Clone:        | WR18  |  |  |  |
| Isotype:      | lgG2a   |  |  |  |
| Quantity:     | 100 TESTS/0.5ml                                   |  |  |  |

# **Product Details**

### **Applications**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <a href="www.bio-rad-antibodies.com/protocols">www.bio-rad-antibodies.com/protocols</a>.

|                | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry |     |    |                | Neat               |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| Target Species         | Human                             |                         |                    |
|------------------------|-----------------------------------|-------------------------|--------------------|
| Product Form           | Purified IgG conjugate            | ed to StarBright Blue 6 | 675 - liquid       |
| Max Ex/Em              | Fluorophore                       | Excitation Max (nm)     | Emission Max (nm   |
|                        | StarBright Blue 675               | 476                     | 675                |
| Preparation            | Purified IgG prepared supernatant | by affinity chromatog   | raphy on Protein G |
| <b>Buffer Solution</b> | Phosphate buffered sa             | aline                   |                    |
| Preservative           | 0.09% Sodium Azide                | (NaN <sub>3</sub> )     |                    |
| Stabilisers            | 1% Bovine Serum Alb               | umin                    |                    |
|                        | 0.1% Pluronic F68                 |                         |                    |
|                        | 0.1% PEG 3350                     |                         |                    |
|                        | 0.05% Tween 20                    |                         |                    |

| ı | m | m   | п | n  | O | a | e | n  |  |
|---|---|-----|---|----|---|---|---|----|--|
|   |   | ••• | u | •• | v | 9 | • | •• |  |

Human HLA Class II (DP, DQ, DR).

#### **Fusion Partners**

Spleen cells from immunized BALB/c mice were fused with cells from NS0 mouse myeloma cell line.

#### Specificity

**Mouse anti Human HLA DP DQ DR antibody, clone WR18** reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.

The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.

## **Flow Cytometry**

Use 5ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.

#### References

- 1. Moore, K. *et al.* (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. <u>J Pathol</u> 152:13-21.
- 2. Trefzer, U. *et al.* (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 85 (5): 618-26.
- 3. Palmer, K.J. *et al.* (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol. 119: 412-8.
- 4. Chia, J.S. *et al.* (2001) Human T-cell responses to the glucosyltransferases of *Streptococcus mutans*. Clin Diagn Lab Immunol. 8: 441-5.
- 5. Keating, S. *et al.* (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol. 76: 8179-88.
- 6. Elias, F. *et al.* (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. <u>J. Immunol.</u> 171: 3697-704.
- 7. Llewelyn, M. *et al.* (2004) HLA class II polymorphisms determine responses to bacterial superantigens. <u>J Immunol</u>. 172 (3): 1719-26.
- 8. Neumann F *et al.* (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 112 (4): 661-8.
- 9. Neumann, F. *et al.* (2004) Identification of an antigenic peptide derived from the cancertestis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. <u>Cancer Immunol Immunother</u>. 53 (7): 589-99.
- 10. Adamski, J. (2004) 17{beta}-Estradiol Inhibits Class II MHC Expression: Influence on Histone Modifications and CBP Recruitment to the Class II MHC Promoter Molecular Endocrinology 18:1963
- 11. Iking-Konert C *et al.* (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. <u>Ann Rheum Dis. 64 (10): 1436-42.</u>
- 12. Hayman, M.W. et al. (2006) Soluble human leukocyte antigen: a diagnostic indicator of

rheumatoid arthritis? J Immunol Methods. 315 (1-2): 19-26.

- 13. Chang, Y.C. *et al.* (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 111: 5054-63.
- 14. del Pilar Martin, M. *et al.* (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. <u>Arch Neurol. 65 (12):</u> 1596-603.
- 15. Litzinger, M.T. *et al.* (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. <u>Cancer Immunol Immunother</u>. 58: 955-65.
- 16. John, J. *et al.* (2010) Differential effects of Paclitaxel on dendritic cell function. <u>BMC</u> Immunol. 11:14.
- 17. Sadallah, S. *et al.* (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. <u>J Immunol.</u> 186: 6543-52.
- 18. Kissner, T.L. *et al.* (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules. PLoS One. 6: e15985.
- 19. Silk, K.M. *et al.* (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. <u>Gene Ther. 19 (10):</u> 1035-40.
- 20. Silk, K.M. *et al.* (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. <u>J Biomed Biotechnol</u>. 2012: 172420.
- 21. Sabbah, S. *et al.* (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. <u>Blood. 119 (9):</u> 2083-92.
- 22. Manna, D. *et al.* (2012) 36-P: WR18 Monoclonal Antibody: A Single Antibody to Detect HLA DR, DP and DQ Antigens. Human Immunol. 73: 72.
- 23. Noble, P. *et al.* (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. <u>Br J Cancer. 108 (10): 2097-105.</u>
- 24. Koschwanez, H. *et al.* (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing. Brain Behav Immun. 50: 47-51.
- 25. Hönger, G. *et al.* (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch. Tissue Antigens. 85 (4): 260-6.
- 26. Ziegler, C.G.K. *et al.* (2019) Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. <u>Cell Rep. 28 (4): 923-937.e3.</u>
- 27. Costa, S.F. *et al.* (2024) MicroRNA-194 regulates parasitic load and IL-1β-dependent nitric oxide production in the peripheral blood mononuclear cells of dogs with leishmaniasis. PLoS Negl Trop Dis. 18 (1): e0011789.

| Storage                          | Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.   |
|----------------------------------|--|
| Guarantee                        | 12 months from date of despatch  |
| Acknowledgements                 | This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts  |
| Health And Safety<br>Information | Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA477SBB675">https://www.bio-rad-antibodies.com/SDS/MCA477SBB675</a> |

**Regulatory** For research purposes only

# **Related Products**

# **Recommended Useful Reagents**

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

North & South Tel: +1 800 265 7376

**Worldwide** Tel: +44 (0)1865 852 700

Europe

Tel: +49 (0) 89 8090 95 21

America Fax: +1 919 878 3751

Fax: +44 (0)1865 852 739

Fax: +49 (0) 89 8090 95 50

Email: antibody\_sales\_us@bio-rad.com

Email: antibody\_sales\_uk@bio-rad.com

Email: antibody\_sales\_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M405196:220916'

#### Printed on 08 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint